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Bacteriophages as Pathogens and Immune Modulators?
A. Lengeling, A. Mahajan, D. L. Gally
The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, United Kingdom
ABSTRACT While Shiga toxins (Stx) are key determinants of enterohemorrhagic Escherichia coli (EHEC) pathophysiology in hu-
mans, their dissemination to target organs following gastrointestinal EHEC infection is still poorly understood. Most types of
Stx target cells with globotriaosylceramide (Gb3) receptors, which are expressed on endothelial cells. According to current the-
ory, Stx is trafficked on the surface of peripheral blood cells, and transfer of toxin from these trafficking cells to endothelial cells
results in microvascular damage to target organs, including the kidneys and brain. Inside the cell, Stx inhibits protein synthesis,
resulting in cell death. Host “repair” responses can lead to microthrombus formation, erythrocyte damage, and reduced oxygen
supply, potentially resulting in organ failure. A recent study [L. V. Bentancor et al., mBio 4(5):e00501-13, 2013, doi:10.1128/
mBio.00501-13] indicates that another mechanism for Stx “dissemination” needs to be considered. Bentancor et al. demon-
strated that high-pressure injection of a plasmid encoding the “prokaryotic” Stx2 sequence into mice can lead to mortality, with
pathology indicative of Stx activity and antibody responses to Stx. While the plasmid levels and injection methodology were ex-
treme, the study indicates that these sequences are potentially taken up into eukaryotic cells, transcribed, and translated, pro-
ducing active Stx. Stx genes are present on integrated bacteriophage genomes in EHEC, and Stx-encoding phages are released
following bacterial lysis in the gastrointestinal tract. We therefore need to consider whether bacteriophage sequences can be ex-
pressed in eukaryotic cells, what the wider implications are for our understanding of many “bacterial” diseases, and the possibil-
ity of developing novel interventions that target bacteriophages.
EHEC AND Stx PATHOLOGY
Enterohemorrhagic Escherichia coli (EHEC) bacteria expressingdifferent types of Shiga toxin (Stx) have emerged over the last
25 years as a serious threat to human health in many parts of the
world. The toxins are important virulence factors of EHEC and
are responsible for the more severe complications of EHEC-
associated infections, such as hemorrhagic colitis and hemolytic-
uremic syndrome (HUS) (1). The toxins have been classified into
two main types (1 and 2) based on differences at the amino acid
level, with more minor variation defining subclasses of Stx2. Both
Stx1 and Stx2 are composed of a pentameric B subunit and a single
A subunit. The B subunit defines cellular targeting to cells that
express the globotriaosylceramide (Gb3, CD77) and to a lesser
extent the globotetraosylceramide (Gb4) glycosphingolipid re-
ceptors on their surfaces. The combined B and A subunits enter
the cell, and the presence of the B subunit is critical inmembrane-
associated trafficking before final release of the A subunit, which
then acts in the endoplasmic reticulum to cleave 28S rRNA and
inhibit protein synthesis (2, 3).
The main issue for human disease is the presence of the Gb3
receptor on endothelial cells that line our vasculature and the
damage and subsequent repair responses in narrow capillaries of
the microvasculature, in particular in the kidney and brain. This
leads to thrombus formation with subsequent red blood cell de-
struction and prevention of blood/oxygen supply, which can in
turn result in loss of tissue function and organ failure. Despite a
sophisticated understanding of Stx activity, how the toxin actually
traffics into systemic circulation from the bacteria in the gastroin-
testinal tract is still far from clear, and a number of mechanisms
have been proposed (Fig. 1). The situation is made more compli-
cated by the fact that the toxin genes are present on lysogenic
bacteriophages and expression of the main Stx2 types requires
induction of the bacterial SOS response with release of toxin oc-
curring upon phage-induced lysis of the bacterial cell (4).
EVIDENCE FOR A NEW VIEWPOINT ON Stx TRAFFICKING
In their recent publication, Bentancor and colleagues (5) provide
evidence that a plasmid encompassing the prophage Stx2 genetic
region can be lethal when injected systemically into mice, with
evidence of Stx2 production and Stx2-induced pathology. The
authors used a high-pressure delivery system to inject a large vol-
ume of plasmid DNA into the animals, which led to perfusion of
the plasmid into different tissues throughout the body, in partic-
ular the liver. While the method of delivery is extreme, the results
indicate that the “prokaryotic” plasmid is potentially taken up by
eukaryotic cells, transcribed, and translated by the cellular ma-
chinery into active Stx. While there are a number of important
possible caveats to this study (including the failure to use germfree
mice, in which potentially transformable bacteria would be ab-
sent), the potential implications are far reaching. The possibility
that Stx production occurs following uptake of Stx-encoding bac-
teriophages into certain types of eukaryotic cells should be tested,
as should the wider possibility that bacteriophage gene expression
is important to the etiology of several “bacterial” diseases. If
proven to be true, this phenomenon opens up new opportunities
for treatments that target the bacteriophage as well as the bacte-
rium and key virulence factors.
In 1971, Merril et al. (6) demonstrated the expression of a
lambdoid phage-encoded -galactosidase in human fibroblasts.
This was clear evidence that eukaryotic cells could take up and
process phage particles, leading to production of a prokaryotic
enzyme. While ground breaking, the pathogenic consequences of
this startling work were, to our knowledge, never followed up. In
the recent Bentancor study, Stx2 bacteriophages were not used,
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FIG 1 Schematic illustration of a proposed mechanism for Stx-encoding bacteriophage (Stx) uptake into eukaryotic cells with subsequent Shiga toxin (Stx)
production following human infection with EHEC. The top panel demonstrates lysis of EHEC in the gastrointestinal tract, with release of both Stx and Stx. Stx
or Stx would have to translocate across the epithelial barrier, and this may involve transfer in or on eukaryotic cells, including intraepithelial lymphocytes
(IELs). Systemic trafficking is shown for Stx in the central section of the figure, but this also applies to Stx. The bottom-left panel shows the production of Stx
in eukaryotic cells in the local lymph nodes following uptake of Stx into cells, in particular monocytes andmacrophages. The Stx produced can have an impact
on local immune responses that feed back to impact the survival of the host bacterial population in the gastrointestinal tract. The right panel shows Stx production
from Stx in the main organs affected during HUS.
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but the possibility remains that some level of Stx production may
occur following uptake of Stx-encoding bacteriophages into spe-
cific eukaryotic cells, including dendritic cells, macrophages, and
neutrophils. Further support for this idea comes from the use of
bacteriophage lambda as a delivery vehicle for DNA vaccines (7).
For vaccines, the antigen of interest is cloned into the bacterio-
phage genome and expression is driven by a strong eukaryotic
promoter, but the point remains that once these bacteriophages
are delivered systemically, then there is amechanism by which the
phage are taken up and the DNA exposed and then transcribed
and translated, leading to sufficient antigen presentation to pro-
duce a decent adaptive immune response.
CONSIDER BOTH BACTERIOPHAGE AND Stx TRAFFICKING IN
THE ETIOLOGY OF EHEC-ASSOCIATED DISEASE
The findings of the Bentancor study necessitate a reevaluation of
the current hypotheses regarding Stx dissemination. It is possible
that these routes also apply to Stx-encoding bacteriophages, in
which case bacteriophage uptake, followed by transcription and
translation in eukaryotic cells, would lead to their systemic spread
and to Stx production at distant sites (Fig. 1). Other hypothetical
mechanisms of Stx dissemination include cell-based delivery of
the toxin from the lumen of the intestine (where it is produced by
the infecting bacteria) to target organs of HUS pathogenesis by
peripheral blood cells, such as granulocytes, monocytes, platelets,
lymphocytes, and erythrocytes (8–12). It has been suggested that
these cells express low-affinity Gb3 receptors which allow Stx2 to
bind, piggyback into the bloodstream, and traffic to endothelial
cells of target organs that express high-affinity Gb3 receptors on
their surface, including the kidneys and brain (9, 10). However,
whether this really occurs in HUS patients is still heavily debated,
since binding of Stx2 to these circulating blood cells could not
always be reproduced in vitro and relevant animal models for in-
vestigation of in vivo Stx2 trafficking and deliverymechanisms are
still absent. Other candidates for Stx2 trafficking include serum
proteins, such as the serum amyloid P component (13), and lipo-
proteins that have Gb3 on their surface (14). The suggestion from
the Bentancor research is that by acting as particles for transduc-
ing Stx-encoding sequences into eukaryotic cells, the bacterio-
phages themselves may also make a more direct contribution to
HUS development as an alternative source of Stx2 production.
ISSUES OF TRANSCRIPTION, TRANSLATION, AND ACTIVITY
In another recent study, Bentancor et al. provided preliminary
data that indicate that the Stx2-encoding plasmid and phage can
lead to expression of cytotoxic Stx2 in Vero cells (15). For Stx
production in eukaryotic cells, the Stx2 sequences would need to
be transcribed and translated.While there is potentially significant
overlap between promoter and enhancer sequence requirements
in prokaryotic and eukaryotic cells, the barriers to translation are
muchmore significant. However, eukaryotic viruses are known to
exploit noncanonical, cap-independent mechanisms, so this
could apply to bacteriophages. It is also possible that the bacterio-
phage exploits gene expression and translation in mitochondria,
given the close links between this organelle and the prokaryotic
world. A further issue would be the site of Stx2 production, the
potential impact of the toxin on the producing cell, and the details
of whether and how the toxin is exported. While the Bentancor
study demonstrated that very high levels of plasmid result in Stx-
related pathology and anti-Stx responses, very low levels of Stx
toxin can still have biological activity. As such, inefficient expres-
sion may still produce enough toxin to have an effect on host cells
and potentially feed back to impact host-bacterium survival, pro-
viding selection pressure for the evolution of the expression away
from the host bacteria.
Stx IMMUNE MODULATION AND THE WIDER CONTEXT
Christian Menge’s work (16) has shown that Stx1 has a clear im-
pact on B and T cell proliferation. Consequently, trafficking of Stx
bacteriophages to local lymph nodes could lead to low levels of
local toxin production, with subsequent immune-modulatory
properties. Taking this one step further, it is interesting that bac-
teriophages associated with a number of pathogenic genera, such
asClostridium and Staphylococcus, are known to encode a number
of toxins and immunomodulatory proteins and these are critical
in defining the virulence of the bacterial pathogen in which they
are hosted. We propose that the research community needs to
consider the possible impact of released bacteriophages in health
and disease and that these bacteriophage-encoded factors may be
expressed away from the bacterium to modify immune responses
that in the end benefit the bacteriophage-bacterium relationship.
Bacteriophages are the most numerous replicating organisms on
the planet and frequently come into contact with animals and
humans. These are predominately prokaryotic DNA viruses, and
perhaps we should not be surprised if they turn out to have a
profound impact on their animal as well as bacterial hosts.
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